USO 24041
Protocol Title: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (V940-009)
Disease Types: Lung Cancer Research
Eligibility Requirements:
• Histologically/cytologically confirmed diagnosis of resectable Stage II, IIIA, or
IIIB (N2) NSCLC
• No prior therapy (except pts enrolled after the neoadjuvant treatment and
surgery)
• Pt who received up to 4 cycles of pembrolizumab and platinum-doublet
chemotherapy, followed by R0 or R1 lobectomy or pneumonectomy, may
enroll if all eligibility criteria are met
• No prior anti-PD(L)1 or with another stimulatory/coinhibitory TCR or cancer
vaccine, including another INT
• Chemotherapy and pembrolizumab followed by surgery will be eligible
• Able to undergo protocol therapy, including necessary surgery
• Documentation of absence of tumor-activating EGFR mutations and ALK
gene rearrangements
• Pt with predominantly squamous histology does not require molecular
testing for EGFR
For more information on this trial CLICK HERE .
Available at: